Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2019 Filed Nov 4, 2019 23:26 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Exercise / conversionOrdinary Shares | 1,202 | $41.60 | $50,003.20 |
DisclosureSEC source: 0001127602-19-031732 · form4.xml · nonDerivative · entry 3 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 23:26 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
SaleOrdinary Shares | 37,774 | $109.50 | $4,136,253.00 |
DisclosureSEC source: 0001127602-19-031732 · form4.xml · nonDerivative · entry 2 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,262 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 23:26 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Exercise / conversionOrdinary Shares | 37,774 | $38.81 | $1,466,008.94 |
DisclosureSEC source: 0001127602-19-031732 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 243 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 22:10 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 65,170 | $106.22 Strike: $106.22 | $6,922,357.40 |
DisclosureSEC source: 0001127602-19-031286 · form4.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,170 Underlying: Ordinary Shares · 65,170 shares Expires 2029-10-28 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 22:10 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantOrdinary Shares | 9,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031286 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,536 F1 · kind: The restrictions on such restricted stock units shall lapse 100% on July 29, 2022 if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 170 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 17,466 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · derivative · entry 11 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,468 Underlying: Ordinary Shares · 17,466 shares Expires 2027-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,983 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · derivative · entry 10 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,328 Underlying: Ordinary Shares · 24,983 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 34,189 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · derivative · entry 9 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,283 Underlying: Ordinary Shares · 34,189 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,569 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · derivative · entry 8 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399 Underlying: Ordinary Shares · 7,569 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 1,594 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,594 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. F4 · derivative.exercise_date: This option to purchase 30,275 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 30,275 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 72,848 | $107.58 | $7,836,987.84 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · nonDerivative · entry 5 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,072 Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionOrdinary Shares | 17,466 | $83.97 | $1,466,620.02 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · nonDerivative · entry 4 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionOrdinary Shares | 24,983 | $88.06 | $2,200,002.98 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · nonDerivative · entry 3 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionOrdinary Shares | 34,189 | $78.00 | $2,666,742.00 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · nonDerivative · entry 2 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:37 UTC |
Surface Carol ASVP, Chief HR Officer
|
Exercise / conversionOrdinary Shares | 7,569 | $62.76 | $475,030.44 |
DisclosureSEC source: 0001127602-19-030510 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:22 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GiftOrdinary Shares | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030330 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,808 Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:22 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GiftOrdinary Shares | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030330 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 GRAT Disclosed balance after: 5,900 Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,995 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · derivative · entry 12 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,995 shares Expires 2020-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 27,353 | $0.00 Strike: $29.52 | $0.00 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · derivative · entry 11 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 Underlying: Ordinary Shares · 27,353 shares Expires 2021-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,817 | $0.00 Strike: $27.29 | $0.00 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · derivative · entry 10 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,817 shares Expires 2020-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Disposition to issuerOrdinary Shares | 2,300 | $109.37 | $251,541.80 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 9 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,917 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.11 to $109.59, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Disposition to issuerOrdinary Shares | 14,517 | $108.40 | $1,573,700.87 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 8 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,217 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.10 to $109.09, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Disposition to issuerOrdinary Shares | 1,050 | $109.35 | $114,819.60 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 7 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,734 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.18 to $109.52, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Disposition to issuerOrdinary Shares | 6,945 | $108.42 | $752,949.12 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 6 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,784 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.17 to $109.13, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Disposition to issuerOrdinary Shares | 3,800 | $109.35 | $415,533.80 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 5 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,729 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 to $109.67, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Disposition to issuerOrdinary Shares | 23,553 | $108.40 | $2,553,239.41 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 4 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,529 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.04, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Exercise / conversionOrdinary Shares | 7,995 | $25.41 | $203,152.95 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 3 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Exercise / conversionOrdinary Shares | 27,353 | $29.52 | $807,460.56 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 2 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 16:54 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
Exercise / conversionOrdinary Shares | 16,817 | $27.29 | $458,935.93 |
DisclosureSEC source: 0001127602-19-029740 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 21:52 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
SaleOrdinary Shares | 100 | $108.21 | $10,821.00 |
DisclosureSEC source: 0001127602-19-029262 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,816 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 21:52 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
SaleOrdinary Shares | 21,325 | $107.51 | $2,292,672.08 |
DisclosureSEC source: 0001127602-19-029262 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,916 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.02 to $107.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 18:20 UTC |
Lenehan James TDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,813 | $0.00 Strike: $44.13 | $0.00 |
DisclosureSEC source: 0001127602-19-029170 · form4.xml · derivative · entry 3 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,813 shares Expires 2020-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 1,813 New Medtronic ordinary shares for $44.13 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,813 Medtronic common stock shares for $44.13 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 18:20 UTC |
Lenehan James TDirector
|
Tax withholdingOrdinary Shares | 744 | $107.62 | $80,069.28 |
DisclosureSEC source: 0001127602-19-029170 · form4.xml · nonDerivative · entry 2 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,720 Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 18:20 UTC |
Lenehan James TDirector
|
Exercise / conversionOrdinary Shares | 1,813 | $44.13 | $80,007.69 |
DisclosureSEC source: 0001127602-19-029170 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 129 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 423 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 25 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272 Underlying: Ordinary Shares · 423 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,121 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 24 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,364 Underlying: Ordinary Shares · 14,121 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 595 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 23 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596 Underlying: Ordinary Shares · 595 shares Expires 2027-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 19,054 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 22 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,055 Underlying: Ordinary Shares · 19,054 shares Expires 2027-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 852 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 21 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 Underlying: Ordinary Shares · 852 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 27,254 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 20 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,085 Underlying: Ordinary Shares · 27,254 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 321 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 19 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 321 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,257 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · derivative · entry 18 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321 Underlying: Ordinary Shares · 10,257 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 423 | $107.22 | $45,354.06 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 17 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 423 | $89.08 | $37,680.84 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 16 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 14,121 | $107.41 | $1,516,764.85 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 15 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.36 to $107.48, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 14,121 | $89.08 | $1,257,898.68 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 14 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 595 | $107.22 | $63,795.90 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 13 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 595 | $83.97 | $49,962.15 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 12 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 19,054 | $107.41 | $2,046,666.36 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 11 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.28 to $107.58, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 19,054 | $83.97 | $1,599,964.38 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 10 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 17:55 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 852 | $107.22 | $91,351.44 |
DisclosureSEC source: 0001127602-19-028265 · form4.xml · nonDerivative · entry 9 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,761 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.